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Introduction
Parkin (PARK2) and PINK1 (PARK6), gene products mutated in 
autosomal recessive forms of Parkinson’s disease (Kitada et al., 
1998; Valente et al., 2004), appear to be involved in mitochon-
drial maintenance in fly (Greene et al., 2003; Clark et al., 2006; 
Park et al., 2006; Yang et al., 2006) and mammalian models 
(Büeler, 2009; Li and Guo, 2009). Genetic studies in Drosophila 
show that PINK1, a kinase located in mitochondria, functions 
upstream of Parkin, an E3 ubiquitin (Ub) ligase located in the 
cytosol, in the same pathway that preserves mitochondrial in-
tegrity (Clark et al., 2006; Park et al., 2006; Yang et al., 2006). 
Interestingly, perturbing mitochondrial dynamics by either pro-
moting fission or suppressing fusion can compensate for pink1 
and parkin mutations (Deng et al., 2008; Poole et al., 2008; 
Yang et al., 2008; Park et al., 2009). Although these studies sug-
gest that PINK1- and Parkin-mediated mitochondrial integrity 
is tightly linked to the regulation of mitochondrial fission, how 
such fission protects mitochondria remains unknown.
Dysfunctional mitochondria may be selectively eliminated 
by autophagy, termed mitophagy (Kim et al., 2007), through 
pathways  distinct  from  bulk  autophagy  that  provide  starved 
cells with nutrients. One pathway of mitophagy appears to be 
activated by Parkin after its translocation from the cytosol spe-
cifically to dysfunctional mitochondria (Narendra et al., 2008). 
Consistent with genetic studies in flies that indicated that they 
work in the same pathway, Parkin translocation and mitophagy 
induction require PINK1 activity (Geisler et al., 2010; Matsuda 
et al., 2010; Narendra et al., 2010; Vives-Bauza et al., 2010). 
Recent studies further show that upon Parkin translocation to 
damaged mitochondria, Parkin E3 Ub ligase activity increases 
(Matsuda et al., 2010), and mitochondrial substrates such as 
VDAC1 become ubiquitinated (Geisler et al., 2010), followed 
by recruitment of p62 and aggregation of mitochondria by the 
HDAC6 deacetylase (Lee et al., 2010) .
D
amage to mitochondria can lead to the depolar-
ization  of  the  inner  mitochondrial  membrane, 
thereby sensitizing impaired mitochondria for   
selective elimination by autophagy. However, fusion of 
uncoupled mitochondria with polarized mitochondria can 
compensate for damage, reverse membrane depolariza-
tion, and obviate mitophagy. Parkin, an E3 ubiquitin li-
gase that is mutated in monogenic forms of Parkinson’s 
disease, was recently found to induce selective autophagy 
of damaged mitochondria. Here we show that ubiquitina-
tion of mitofusins Mfn1 and Mfn2, large GTPases that   
mediate mitochondrial fusion, is induced by Parkin upon 
membrane depolarization and leads to their degradation 
in a proteasome- and p97-dependent manner. p97, a 
AAA+ ATPase, accumulates on mitochondria upon un-
coupling of Parkin-expressing cells, and both p97 and 
proteasome activity are required for Parkin-mediated   
mitophagy. After mitochondrial fission upon depolariza-
tion, Parkin prevents or delays refusion of mitochondria, 
likely by the elimination of mitofusins. Inhibition of Drp1-
mediated mitochondrial fission, the proteasome, or p97 
prevents Parkin-induced mitophagy.
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(HeLa: YFP-Parkin). Endogenous Mfn1 and Mfn2 expression 
was not affected by YFP-Parkin in untreated cells, whereas their 
expression levels were greatly decreased after the addition of 
CCCP to HeLa: YFP-Parkin cells (Fig. 1, d and e). Furthermore, 
MG132 inhibited the elimination of Mfn1 and Mfn2, and also 
generated higher molecular weight bands of Mfn1, which is sug-
gestive of ubiquitination (Fig. 1 a and d, MG132 plus lanes). Mfn 
levels were not reduced upon CCCP addition to HeLa cells not 
expressing YFP-Parkin. These data indicate that Parkin expres-
sion, when combined with mitochondrial  uncoupling, induces 
mitofusin degradation via the Ub–proteasome system (UPS).
We compared the time course of YFP-Parkin translocation 
to mitochondria with that of mitofusin degradation after mito-
chondrial uncoupling. As shown in Fig. 1 f, 60 min after trigger-
ing mitochondrial depolarization with CCCP, the proportion of 
mitochondrial YFP-Parkin increased substantially, whereas   
mitofusin protein levels were drastically reduced. Both Mfn1 
and Mfn2 are degraded in a Parkin-dependent manner, although 
Mfn1 degradation appears to be generally more robust than 
Mfn2 degradation. Interestingly, higher molecular weight bands 
of YFP-Parkin were also detected coincident with the time of 
mitochondrial translocation of Parkin. These high molecular 
weight Parkin bands were detected with YFP-Parkin and not 
with untagged Parkin, which is consistent with recent studies sug-
gesting that the GFP portion of GFP-Parkin is a pseudo-substrate 
for Parkin (Matsuda et al., 2010). This also suggests that the E3 
ligase activity of Parkin is activated upon mitochondrial trans-
location. Simultaneous imaging of mCherry-Parkin and Mfn2-
YFP expressed in HeLa cells after CCCP treatment also revealed 
a decrease in Mfn2-YFP signal, whereas untreated cells exhib-
ited stable Mfn2-YFP intensity (Fig. 1 g and Fig. S2 a), which 
further indicated that CCCP-induced mitochondrial transloca-
tion of Parkin initiated degradation of mitofusin protein.
We also determined whether endogenous Mfn1 becomes 
ubiquitinated upon Parkin translocation to mitochondria. To this 
end, we applied denatured Mfn1 immunoprecipitation (IP) from 
control and CCCP-treated SH-SY5Y cells. The data show that 
CCCP treatment induces high molecular weight species of Mfn1 
(Fig. 2 a) that accumulated to even greater extents upon MG132 
and  CCCP  cotreatment.  Importantly,  these  high  molecular 
weight species of Mfn1 cross-reacted with anti-Ub antibodies 
(Fig. 2 a, bottom). We also examined Mfn1 ubiquitination in 
HeLa cells with and without stable Parkin expression. As with 
SH-SY5Y cells, ubiquitinated Mfn1 was detected specifically 
after CCCP treatment in HeLa: YFP-Parkin cells, whereas no 
Mfn1 ubiquitination was detected after CCCP treatment of con-
trol HeLa cells (Fig. 2 b).
Overall, these data indicate that Mfn1 is ubiquitinated and 
degraded in Parkin-dependent manner. To test this possibility 
further by knocking down PARK2 (Parkin) in SH-SY5Y cells, 
we examined whether Mfn degradation requires endogenous 
Parkin expression. We found that PARK2 knockdown inhibits 
Mfn degradation upon CCCP treatment (Fig. 2, c and d, PARK2 
siRNA), which confirmed the essential role of Parkin in CCCP-
induced Mfn degradation. We also determined whether patho-
genic variants of Parkin affect the Mfn1/2 degradation process. 
To achieve this, we applied two Parkin mutants: Parkin
R275W, 
Mitochondria function in a dynamic network constantly 
fusing and dividing through the activity of large GTPases and 
auxiliary proteins. When damaged mitochondria lose mem-
brane potential, fission, or lack of fusion, can segregate them 
from the mitochondrial network, where they can be engulfed 
by autophagosomes (Twig et al., 2008). Here we show that 
Parkin  induces  the  ubiquitination  of  mitofusins  Mfn1  and 
Mfn2, large GTPases that mediate mitochondrial fusion, lead-
ing to their degradation in both a proteasome- and a AAA+ 
ATPase p97-dependent manner upstream of mitophagy. Upon 
depolarization,  Parkin  prevents  or  delays  refusion  of  mito-
chondria, likely by the elimination of mitofusins. These find-
ings illuminate how Parkin may stimulate mitophagy by the 
manipulation of mitochondrial dynamics and suggest how de-
creasing mitofusin expression in the fly compensates for loss 
of Parkin or PINK1. Consistent with our results in mammalian 
cells, it was recently shown that the expression level of endog-
enous Marf, a fly mitofusin orthologue, was altered by Parkin 
and PINK1 expression (Poole et al., 2010), and Marf (Ziviani 
et al., 2010) was found to be ubiquitinated dependent on Parkin 
and PINK1 expression.
Results
Parkin and PINK1 mediate Mitofusin 
ubiquitination and proteasomal degradation
Most known E3 Ub ligase substrates of Parkin have been identi-
fied in the cytosol, where Parkin normally localizes (Matsuda 
and Tanaka, 2010). To identify potential Parkin substrates on 
mitochondria after depolarization and Parkin translocation, we 
examined the level of various mitochondrial proteins in the   
human  neuroblastoma  cell  line  SH-SY5Y,  which  expresses   
endogenous Parkin (Lutz et al., 2009). 2 h after adding the mito-
chondrial uncoupler carbonyl cyanide m-chlorophenylhydrazone 
(CCCP) to depolarize the mitochondria, we observed the se-
lective reduction in expression of endogenous Mfn1 and Mfn2,   
human homologues of yeast Fzo1 that is known to be degraded 
by the proteasome (Fig. 1 a and b; Neutzner and Youle, 2005). 
None of the other mitochondrial proteins examined displayed a 
reduction in protein levels, whereas Opa1 was cleaved as previ-
ously described (Ishihara et al., 2006; Griparic et al., 2007).   
Incubation of cells with a proteasome inhibitor, MG132, pre-
vented the CCCP-induced decrease in Mfn1 and Mfn2 levels, 
which suggests that they are degraded by the proteasome. As the 
mitochondrial  respiratory  chain  inhibitor  rotenone  has  been 
used to generate an animal model of Parkinsonism (Betarbet   
et al., 2000) and the oxidizing agent and herbicide paraquat has 
been linked to human Parkinsonism (Cochemé and Murphy, 
2008; Brooks et al., 1999), we examined their effects on Mfn 
degradation. After a 24-h exposure to paraquat, SH-SY5Y cells 
display a clear decrease in levels of Mfn1 and 2 (Fig. 1 c). Rote-
none treatment causes a more minor effect consistent with its 
weaker effect on Parkin translocation to the mitochondria (un-
published data). To specifically test the role of Parkin in mitofusin 
elimination, we compared Mfn levels in HeLa cells, which ex-
press little or no endogenous Parkin (Denison et al., 2003; Pawlyk   
et al., 2003), and in HeLa cells stably expressing YFP-Parkin 1369 PINK1- and Parkin-mediated proteasomal degradation of Mfn1 and Mfn2 • Tanaka et al.
using PINK1 RNAi whether PINK1 is also required for CCCP-
induced Mfn proteasomal degradation in the context of endog-
enous Parkin expression. The data show that RNAi-mediated 
depletion  of  PINK1  expression  in  Parkin-expressing  M17   
human neuroblastoma cells inhibited degradation of Mfn1 and 
Mfn2 (Fig. 3, a and b).
To  further  test  the  significance  of  Parkin  activity  for 
CCCP-induced Mfn degradation, we used an alternative strat-
egy to inhibit endogenous Parkin activation. In contrast to inhi-
bition of transcription, inhibition of translation by treatment 
which translocates to depolarized mitochondria but fails to   
induce mitophagy; and Parkin
C441R, which fails to translocate to 
mitochondria (Narendra et al., 2010). In contrast to transient 
expression of wild-type YFP-Parkin, expression of neither   
YFP-Parkin
R275W nor YFP-Parkin
C441R induced Mfn1/2 elimina-
tion upon CCCP treatment (Fig. 2, e and f).
PINK1, a mitochondrial kinase, is essential for the Parkin 
translocation to depolarized mitochondria and for Parkin-mediated 
mitophagy (Geisler et al., 2010; Matsuda et al., 2010; Narendra 
et al., 2010; Vives-Bauza et al., 2010). Therefore, we determined 
Figure 1.  Mitochondrial depolarization induces selective degradation of mitofusins by Parkin. (a) Whole cell lysates of SH-SY5Y cells (30 µg of proteins) 
were subjected to SDS-PAGE after treatment with DMSO (control), CCCP (depolarized), or CCCP with a proteasomal inhibitor, MG132. Immunoblotting 
results show the stability of mitofusin 1 (Mfn1), mitofusin 2 (Mfn2), Opa1, Fis1, Drp1, VDAC, Tim23, Hsp60, Bip, and Parkin. CCCP, 20 µM for 2 h; 
MG132, 30 µM, 30 min prior and with CCCP. A single asterisk on the Mfn2 panel indicates a nonspecific band and the double asterisks indicates a 
cross-reactive band to Mfn1 (Fig. S1, a and b). Opa1 shows conversion from a long form (L) to a shorter form (S) upon depolarization. (b) The average 
of the Mfn1 or Mfn2 levels normalized to the level of Tim23 is presented with standard deviation indicated by the error bars. Each graph was generated 
from three independent experiments as described for panel a. The protein levels in control (nontreated) cells were set as 1. (c) Whole cell lysates (30 µg of 
proteins) of SH-SY5Y cells subjected to SDS-PAGE after treatments with DMSO, Rotenone, or Paraquat are shown. An asterisk on the Mfn2 panel indicates 
a nonspecific band and the double asterisks indicate a cross-reactive band to Mfn1. Rotenone, 100 nM for 24 h; Paraquat, 2 mM for 24 h. (d) Whole cell 
lysates (10 µg of proteins) of HeLa cells or HeLa cells stably transfected with YFP-Parkin were subjected to SDS-PAGE after treatment with DMSO, CCCP, or 
CCCP with MG132. An asterisk on the Mfn2 panel indicates a nonspecific band and the double asterisks indicate a cross-reactive band to Mfn1. CCCP, 
10 µM for 90 min; MG132, 30 µM, 30 min prior and with CCCP. (e) The average of Mfn1 or Mfn2 levels normalized to the level of Tim23 is presented 
with standard deviation indicated by the error bars. Each graph was generated from three independent experiments from d. The protein levels in control 
(nontreated, HeLa cells stably transfected with YFP-Parkin) cells were set as 1. Molecular mass is indicated in kilodaltons next to the gel blots. (f) Whole 
cell lysates of HeLa cells stably transfected with YFP-Parkin (top, 10 µg of proteins) were fractionated into mitochondrial and the postmitochondrial fractions 
(bottom). The asterisk on the Mfn2 panel indicates a nonspecific band, and the double asterisks indicate a cross-reactive band to Mfn1. CCCP, 10 µM.   
(g) HeLa cells transiently expressing Mfn2-YFP and mCherry-Parkin were treated with DMSO or CCCP. After 30 min of CCCP or DMSO treatment (time 
30’), live cell images were captured every 5 min by confocal microscopy. CCCP, 10 µM. Bar, 10 µm.JCB • VOLUME 191 • NUMBER 7 • 2010   1370
Figure  2.  Mitofusin  ubiquitination  requires  Parkin 
ligase activity. (a and b) SH-SY5Y (a), HeLa cells, or 
HeLa cells stably transfected with YFP-Parkin (b) were 
collected  as  cell  lysates  with  denaturing  buffer  (see 
Materials and methods), then subjected to IP with anti-
Mfn1 antibody. IP products were detected with anti-
Mfn1 and anti-Ub (P4D1). CCCP, 10 µM for 2 h for 
SH-SY5Y cells, 90 min for HeLa cells; MG132, 30 µM, 
30 min prior and with CCCP. (c) Whole cell lysates of 
SH-SY5Y cells transfected with control siRNA or PARK2 
siRNA were treated with DMSO or CCCP. An asterisk 
on the Mfn2 panel indicates a nonspecific band and 
the double asterisks indicate a cross-reactive band to 
Mfn1. CCCP, 20 µM for 2 h. (d) The average of the 
Mfn1 or Mfn2 level normalized to the level of Tim23 
is presented with standard deviation indicated by the 
error bars. Each graph was generated from three in-
dependent experiments from c. The protein levels in 
control (nontreated, control siRNA) cells were set as 1. 
(e) HeLa cells transiently transfected with wild-type or 
two patient mutations of YFP-Parkin were treated with 
or without CCCP. Whole cell lysates were subjected 
to immunoblotting with anti-Mfn1, Mfn2, Parkin, and 
Tim23. CCCP, 10 µM for 90 min. An asterisk on the 
Mfn2 panel indicates a nonspecific band and the dou-
ble asterisks indicates a cross-reactive band to Mfn1. 
Molecular mass is indicated in kilodaltons next to the 
gel blots. (f) The average of the Mfn1 or Mfn2 lev-
els normalized to the level of Tim23 is presented with 
standard deviation indicated by the error bars. Each 
graph was generated from three independent experi-
ments from e. The protein levels in control (nontreated, 
with each YFP-Parkin expression) cells were set as 1.1371 PINK1- and Parkin-mediated proteasomal degradation of Mfn1 and Mfn2 • Tanaka et al.
To establish more directly that the ubiquitination of Mfn1 is 
mediated by Parkin, we reconstituted the ubiquitination process   
using a cell free system. As Mfn1 has two hydrophobic domains 
spanning the outer mitochondrial membrane (OMM), we used iso-
lated mitochondria as a source of Mfn1 substrate to combine with 
purified  recombinant  maltose-binding  protein  (MBP)-tagged   
Parkin (MBP-Parkin) and purified UbcH7, an E2 Ub-conjugating   
enzyme  found  to  function  with  Parkin  (Matsuda  et  al.,  2006).   
Consistent with the in vivo data, we found that a high molecular 
weight ladder of Mfn1 appeared more prominent when the mito-
chondria were isolated from CCCP-treated HeLa cells, as compared 
with cycloheximide (CHX) prevents both the CCCP-dependent 
induction  of  PINK1  expression  and  Parkin  translocation  to 
CCCP-uncoupled mitochondria (Narendra et al., 2010). Thus, 
we tested whether CHX would block Mfn1/2 degradation in 
CCCP-treated HeLa: YFP-Parkin cells and SHSY5Y cells. The 
data show that cotreatment of cells with CHX and CCCP com-
pletely prevents Mfn degradation (Fig. 3, c–f), which further 
supports the scenario in which Mfn ubiquitination and degrada-
tion not only requires endogenous PINK1 but also PINK1 accu-
mulation and PINK1-dependent mitochondrial accumulation of 
Parkin during CCCP treatment.
Figure 3.  Mitofusin degradation requires PINK1 expression. (a) M17 cells expressing control or PINK1 shRNA were treated with CCCP or CCCP plus 
MG132. Lysates were immunoblotted with anti-Mfn1, Mfn2, PINK1, and Tim23. CCCP, 20 µM for 4 h; MG132, 30 µM, 30 min prior and with CCCP.   
(b) The average of Mfn1 or Mfn2 levels normalized to the level of Tim23 is presented with the standard deviation indicated by the error bars. Each graph was 
generated from three independent experiments from panel a. The protein levels in control (nontreated, control shRNA) cells were set as 1. (c) HeLa cells 
stably transfected with YFP-Parkin were pretreated with CHX before treatment with CCCP, as indicated on top. Lysates were immunoblotted with anti-Mfn1, 
Mfn2, PINK1, and Tim23. CCCP, 10 µM for 90 min; CHX, 100 µM, 30 min prior as a pretreatment and during incubation with or without CCCP. (d) The 
average of the Mfn1 or Mfn2 level normalized to the level of Tim23 is presented with the standard deviation indicated by the error bars. Each graph was 
generated from three independent experiments from c. The protein levels in control (nontreated) cells were set as 1. (e) SH-SY5Y cells were pretreated with 
CHX before the treatments of CCCP, as indicated on top. Lysates were immunoblotted with anti-Mfn1, Mfn2, PINK1, and Tim23. CCCP, 20 µM for 2 h; 
CHX, 100 µM, 30 min prior as a pretreatment and during incubation with or without CCCP. Molecular mass is indicated in kilodaltons next to the gel blots. 
(f) The average of the Mfn1 or Mfn2 level normalized to the level of Tim23 is presented with the standard deviation indicated by the error bars. Each graph 
was generated from three independent experiments from e. The protein levels in control (nontreated) cells were set as 1.JCB • VOLUME 191 • NUMBER 7 • 2010   1372
Role of p97 in Mfn proteasomal 
degradation
How membrane-spanning proteins such as the mitofusins are 
extracted from the OMM before their proteasomal degradation 
is currently unknown. We therefore examined if Mfn degrada-
tion requires the activity of p97, a AAA+ ATPase involved in 
the retrotranslocation of ER membrane-spanning proteins after 
ubiquitination and en route to proteasomal degradation (Ye   
et al., 2001; Rabinovich et al., 2002). To test this notion, we 
overexpressed wild-type p97 and the dominant-negative mutant 
p97 (E305Q/E578Q; p97
QQ; Ye et al., 2003) in HeLa cells with 
or without transient Parkin expression. We found that Parkin-
mediated Mfn1 ubiquitination was more apparent, and Mfn1 
degradation was largely prevented by expression of the p97
QQ 
(Fig. 5, a–c, p97
QQ), which suggests that p97 mediates degrada-
tion of ubiquitinated Mfn1. Additionally, we found that over-
expression of p97
QQ slowed down the turnover rate of Mfn1   
(Fig. S4, c and d) in control HeLa cells, which suggests that the 
UPS, through the p97 activity, might also mediate steady-state 
Mfn1 ubiquitination and degradation in the absence of mito-
chondrial uncoupling and Parkin expression.
To further test the role and mechanism of p97 in Parkin-
dependent  degradation  of  Mfn  proteins,  we  examined  the   
subcellular localization of p97 under conditions of inducing 
Parkin translocation to mitochondria. After 90 min of CCCP 
treatment, endogenous p97 accumulated on mitochondria in 
HeLa cells transiently expressing YFP-Parkin (Fig. 5 d) but 
not in control HeLa cells or cells treated with tunicamycin,   
a stressor of the ER. The accumulation p97 on mitochondria 
with control HeLa cells (Fig. 4 a). Furthermore, high molecular 
species of Mfn1 were detectable in mitochondrial fractions from 
CCCP-treated HeLa cells incubated with wild-type MBP-Parkin, 
but not recombinant MBP-Parkin
T415N (Fig. 4 a), which is a Parkin-
son’s disease patient mutation lacking E3 ligase activity (Matsuda 
et al., 2006). Using IP with the anti-Mfn1 antibody under denatur-
ing conditions, we confirmed that these high molecular weight 
bands of Mfn1 were also detected with an anti-Ub antibody. Col-
lectively, these results indicate that Parkin promotes ubiquitination 
of Mfn1 and that this ubiquitination can be recapitulated under   
in vitro conditions, which suggests a direct role of Parkin in ubiqui-
tination of Mfn1. However, as mitochondria express at least one 
membrane-spanning E3 Ub ligase, MARCH5 (Karbowski et al., 
2007), Parkin could be activating another E3 ligase to ubiquitinate 
mitofusins. To determine whether MARCH5 is required for   
Parkin-dependent Mfn ubiquitination, we used wild-type HCT116 
or MARCH5
/ HCT116 cell lines that express abundant endoge-
nous Parkin (Fig. S3 b). After CCCP treatment for 3 h, Mfn1 and 
Mfn2 levels decreased comparably in HCT116 or HCT116 
MARCH5
/ cells (Fig. S3 b), which suggests that Parkin-induced 
Mfn degradation occurs in a MARCH5-independent manner.
We also asked whether Parkin might bind to Mfn1/2. The 
data show that in HeLa: YFP-Parkin cells, YFP-Parkin co-
immunoprecipitated with endogenous Mfn1 and Mfn2, and that 
these interactions increased upon CCCP-induced depolariza-
tion of mitochondria (Fig. 4 b). In sum, molecular interactions of   
Parkin with Mfn1 and Mfn2 as well as cell free Parkin-dependent 
ubiquitination of Mfn proteins indicate that Parkin-mediated 
ubiquitination of Mfn1 and Mfn2 might be direct.
Figure  4.  Mitofusin  ubiquitination  requires 
Parkin  and  depolarization  of  mitochondria.  
(a) Mitochondrial fractions (30 µg) from HeLa 
cells treated with or without CCCP and recom-
binant  MBP-Parkin  wild-type  or  MBP-Parkin 
T415N proteins (left) were subjected to the   
in vitro ubiquitination assay (right). Isolated 
mitochondria were incubated with MBP-Parkin 
wild type or T415N. Reaction mixtures were 
subjected to the denatured IP with anti-Mfn1 
antibody as in Fig. 2. IP products were detected 
with anti-Mfn1 and anti-Ub (P4D1). UbcH7 
was used as an E2 enzyme. The asterisk indi-
cates a nonspecific band from MBP proteins 
or other reaction components. (b) HeLa cells 
or HeLa cells stably transfected with YFP-Parkin 
were subjected to nondenaturing IP with anti-
Parkin antibody (PRK8). IP products were de-
tected by anti-Parkin, Mfn1, and Mfn2. CCCP, 
10 µM for 90 min; MG132, 30 µM, 30 min 
prior and with CCCP. An asterisk on the Mfn2 
panel  indicates  a  nonspecific  band  and  the 
double asterisks indicate a cross-reactive band 
to Mfn1. Molecular mass is indicated in kilo-
daltons next to the gel blots.1373 PINK1- and Parkin-mediated proteasomal degradation of Mfn1 and Mfn2 • Tanaka et al.
p97 is required for PINK1–Parkin- 
mediated mitophagy
We examined if p97 activity is required for PINK1–Parkin   
-mediated mitophagy after mitochondrial depolarization. After 
24 h of treatment with CCCP, overexpression of p97
QQ strongly 
inhibited  mitochondrial  elimination,  which  suggests  that 
degradation  of  Mfn  (or  other  ubiquitinated  mitochondrial 
proteins) is required for Parkin-induced mitophagy (Fig. 6, 
c and d). We also investigated whether proteasome activity 
is required for Parkin-mediated mitophagy. To achieve this, HeLa 
cells transiently expressing YFP-Parkin were either treated 
with  CCCP  alone  or  cotreated  with  CCCP  and  MG132.   
Indeed, after 24 h of CCCP treatment, YFP-Parkin eliminated 
all detectable mitochondria from 80% of cells, whereas 
<10% of CCCP- and MG132-cotreated cells displayed com-
plete mitochondrial loss (Fig. 6, e and f). Because YFP-Parkin 
showed a similar efficiency of translocation to mitochondria 
after CCCP with and without MG132 treatment (Fig. 6 e,   
60’ and 4 h), the inhibition of mitochondrial elimination by 
upon Parkin translocation was confirmed by the data showing 
that Myc-p97 also translocated to the mitochondria in CCCP-
treated Parkin-expressing cells. Interestingly, both wild-type 
Myc-p97 and Myc-p97
QQ accumulated on mitochondria upon 
CCCP treatment in HeLa cells transiently expressing YFP-
Parkin, but not on mitochondria in control HeLa cells lacking 
Parkin expression (Fig. 5, e and f). These data indicate that 
p97 accumulation on mitochondria requires Parkin expression 
and mitochondrial depolarization, and occurs independently 
of p97 ATPase activity.
Next, we examined whether PINK1 is required for mito-
chondrial accumulation of p97. In PINK1 knockout mouse embry-
onic fibroblasts (PINK1
/MEFs), mitochondrial accumulation   
of p97 was not detectable upon CCCP treatment (Fig. 6 a), 
which indicates that p97 translocation is triggered by the ac-
tivation  of  PINK1–Parkin  activity  upon  depolarization  of 
mitochondria. This was further supported by data showing that 
p97  accumulated  specifically  on  uncoupled,  Parkin-positive, 
and Ub-positive mitochondria (Fig. 6 b).
Figure 5.  AAA+ ATPase p97 mediates mitofusin degradation and accumulates on mitochondria after depolarization. (a) HeLa cells or HeLa cells transiently 
expressing Parkin were transfected with wild-type Myc-p97 or dominant-negative Myc-p97
QQ (E305Q/E578Q). After treatment with 10 µM FCCP for the 
indicated times, cells and mitochondrial fractions were collected as in Fig. 1 f. (b) The average of ubiquitinated (top) or nonubiquitinated (bottom) Mfn1 or 
Mfn2 normalized to the level of Tom20 is presented with the standard deviation indicated by the error bars. Each graph was generated from three indepen-
dent experiments from panel a. The protein levels at time 0 were set as 1. (c) HeLa cells stably transfected with YFP-Parkin were transiently transfected with 
Myc-p97
QQ and collected as cell lysates with denaturing buffer, then subjected to IP with anti-Mfn1 antibody. IP products were detected with anti-Mfn1 and 
anti-Ub (P4D1). CCCP, 10 µM for 90 min. Molecular mass is indicated in kilodaltons next to the gel blots. (d) HeLa cells or HeLa cells transiently transfected 
with YFP-Parkin were treated with DMSO, Tunicamycin, or CCCP. Cells were immunostained with anti-p97 and anti-Tom20. The boxed regions are magni-
fied in the bottom panels. Tunicamycin, 5 µg/ml for 6 h; CCCP, 10 µM for 90 min. (e and f) HeLa cells transiently transfected with YFP-Parkin and wild-type 
Myc-p97 or Myc-p97
QQ were treated with DMSO (e) or CCCP (f). Cells were fixed and immunostained with anti-Myc and anti-Tom20 antibodies. The boxed 
regions are magnified in the bottom panels. CCCP, 10 µM for 90 min. Bars: (top panels) 10 µm; (bottom enlarged panels) 1 µm.JCB • VOLUME 191 • NUMBER 7 • 2010   1374
Figure 6.  p97 recruitment to ubiquitinated mitochondria mediates PINK1–Parkin-induced mitochondrial elimination. (a) MEFs from PINK1
+/+ or PINK1
/ 
mice were transiently transfected with YFP-Parkin and Myc-p97. Cells were treated with DMSO or CCCP, then immunostained with anti-Myc and anti– 
cytochrome c. CCCP, 20 µM for 2 h. Bar, 10 µm. (b) HeLa cells transiently expressing Myc-p97 or YFP-Parkin/Myc-p97 were treated with DMSO or 
CCCP. Cells were immunostained with anti-Myc and anti-Ub (fk1). CCCP, 10 µM for 90 min. The boxed regions are magnified in the bottom panels.   
(c) HeLa cells were transiently transfected with YFP-Parkin and wild-type Myc-p97 or Myc-p97
QQ. After treatment with CCCP for 24 h, cells were fixed and 
immunostained with anti-Myc and anti-Tom20 antibodies. CCCP, 10 µM. The boxed regions are magnified in the bottom panels. Bars: (top panels) 10 µm; 
(bottom enlarged panels) 1 µm. (d) Parkin-induced mitophagy in cells shown as in c was quantified (n > 50). CCCP, 10 µM for 24 h. Data represent the 
mean ± SD with P values of at least three replicates. (e) HeLa cells or HeLa cells expressing YFP-Parkin were treated with CCCP or CCCP plus MG132. 
Mitochondria were immunostained with anti-Tom20. Cells expressing YFP-Parkin are indicated with asterisks. CCCP, 10 µM for 24 h; MG132, 30 µM   
30 min prior and with CCCP. Bar, 10 µm. (f) MG132 blocks Parkin-induced mitophagy in HeLa cells as in d. A quantification is shown. Data represent the 
mean ± SD with P values of at least three replicates.1375 PINK1- and Parkin-mediated proteasomal degradation of Mfn1 and Mfn2 • Tanaka et al.
wild-type MEFs (Fig. 8 a, 24 h CCCP; and Fig. 8 g), whereas 
YFP-Parkin recruitment (Fig. 8 f) and Mfn elimination (Fig. 8,   
b and c) were identical in these two cell types. To quantify mito-
chondrial interconnectivity in the DRP1
/MEFs, we applied 
FRAP analysis of mito-YFP as described in Fig. 7 (e and f).   
As expected, mitochondria in DRP1
/ MEFs transiently express-
ing  mCherry-Parkin  were  more  interconnected  after  CCCP 
treatment than in similarly treated wild-type MEFs (Fig. 8, d 
and e). These results indicate that inhibiting mitochondrial fis-
sion hinders Parkin-induced mitophagy. We also extended the 
results in DRP1
/ MEFs to DRP1 knockdown HeLa cells. As 
in the DRP1
/ MEFs, DRP1 knockdown HeLa cells transiently 
expressing  YFP-Parkin  and  treated  with  CCCP  displayed 
clumped mitochondria (Fig. 8 h, CCCP 24 h) and an 80% de-
crease in mitophagy (Fig. 8 i) relative to control cells. Thus, in 
both DRP1
/ MEFs and DRP1 knockdown cells, mitophagy is 
inhibited. This indicates that counteracting mitochondrial fis-
sion, which is a normal function of Mfn1/2, inhibits Parkin- 
mediated mitophagy.
Collectively, we hypothesize that mitofusin degradation 
by mitochondria-associated Parkin inhibits the fusion of dam-
aged mitochondria with healthy mitochondria, thereby segre-
gating the impaired mitochondria from the network of fully 
functional mitochondria to facilitate their selective elimination 
by autophagy.
Discussion
Parkin, an E3 Ub ligase, and PINK1, a mitochondrial kinase, 
are mutated in certain familial forms of Parkinson’s disease 
(Kitada et al., 1998; Valente et al., 2004). Recent studies in   
Drosophila by several groups put these two gene products in the 
same molecular pathway (Clark et al., 2006; Park et al., 2006; 
Yang et al., 2006) and link Parkin and PINK1 to mitochondrial 
fission pathways (Deng et al., 2008; Poole et al., 2008; Yang   
et al., 2008; Park et al., 2009). Loss of mitofusin function or   
mitofusin knockdown partially compensates for PINK1 or Par-
kin deficiencies, which suggests that PINK1 and Parkin may 
normally function in a pathway linked to mitochondrial fission. 
Here we show that Parkin can mediate the ubiquitination and 
proteasomal degradation of Mfn1 and Mfn2. Mfn1 appears to 
be more rapidly degraded than Mfn2 via Parkin, and this may 
relate to differential activity of the two proteins in mitochon-
drial fusion (Cipolat et al., 2004). These results suggest how 
Parkin might intersect the mitochondrial fission and fusion path-
ways consistent with a normal role in promoting mitochondrial 
fission. Our finding that the uncoupling of mitochondria, a con-
dition that causes Parkin translocation to mitochondria, stimu-
lates mitofusin degradation also points to a vital role for mitofusin 
degradation in Parkin-mediated mitophagy. Parkin can initiate 
mitophagy in MFN1/MFN2 double knockout cells, which indi-
cates that mitofusin ubiquitination and proteasomal degradation 
are not essential to activate mitophagy (Fig. 8, j and k). This is 
consistent with genetic studies in flies that loss of mitofusin (Marf, 
a fly Mfn orthologue) compensates for loss of Parkin. Therefore 
we propose that mitofusin degradation does not serve as a signal 
for mitophagy activation, but Mfn1 and Mfn2 removal might be 
MG132 suggests that Parkin-dependent degradation of dys-
functional mitochondria requires not only autophagy, but also 
the UPS.
Mitochondrial fusion inhibition and  
Parkin-mediated mitophagy
In Drosophila, either promoting fission of mitochondria or sup-
pressing fusion partially rescues the swollen mitochondrial pheno-
type of the pink1 and parkin mutant flies (Deng et al., 2008; 
Poole et al., 2008; Yang et al., 2008; Park et al., 2009). This sug-
gests that the PINK1–Parkin pathway may normally promote 
fission of mitochondria. In addition, recent work indicates that 
mitochondrial fission is required for the progression of mitoph-
agy (Nowikovsky et al., 2007; Twig et al., 2008; Kanki et al., 
2009),  which  suggests  that  promoting  mitochondrial  fission 
could compensate for a mitophagy deficit in Parkin-defective 
flies. Loss of mitofusins would be expected to inhibit mito-
chondrial fusion, perhaps fostering the autophagic elimination of   
depolarized mitochondria by segregating them from the mito-
chondrial network. We found that upon mitochondrial depolar-
ization, Opa1 cleavage (Ishihara et al., 2006; Griparic et al., 
2007) occurs more rapidly than mitofusin degradation (unpub-
lished data), which suggests that the elimination of mitofusins 
does not cause the initial mitochondrial fragmentation but might 
delay fusion of mitochondria after uncoupler-induced fragmen-
tation. To determine whether Parkin inhibits fusion of depolar-
ized mitochondria independently of Opa1 cleavage, we examined 
the  rate  of  recovery  of  tubular  mitochondria  after  CCCP- 
induced depolarization and fragmentation of these organelles. 
Pretreatment  with  CCCP  for  90  min  generated  depolarized, 
fragmented, Parkin-positive, and Mfn-negative mitochondria in 
HeLa: YFP-Parkin cells (Fig. 7, a–d, time 0). We then washed 
out the CCCP and analyzed the recovery of the tubular mito-
chondrial networks. After removing the CCCP, the recovery of 
mitochondrial networks in HeLa: YFP-Parkin cells was slower 
than in control HeLa cells (Fig. 7, b and d), despite the equal re-
covery of the longer form of Opa1 detectable both in the pres-
ence and absence of YFP-Parkin (Fig. 7 c). To further test the 
effect of Parkin on mitochondrial connectivity after CCCP wash-
out phenotypes in Fig. 7 b, we applied a FRAP assay (Rizzuto   
et al., 1998; Karbowski et al., 2007). The fluorescence recovery 
of mitochondrial matrix-targeted YFP (mito-YFP) was analyzed 
in HeLa cells transiently expressing mCherry or mCherry-Parkin. 
The data show that at 90 min after CCCP washout, mCherry-
expressing HeLa cells displayed a faster recovery of mito-YFP 
fluorescence compared with mCherry-Parkin–expressing cells 
(Fig. 7, e and f [P = 0.0002, n = 30]; and Fig. S5 a). These   
results suggest that Mfn1/2 degradation promoted by Parkin 
maintains mitochondria fragmentation after mitochondrial de-
polarization.  Parkin  may  therefore  retain  mitochondria  in  a 
fragmented state in order to facilitate mitophagy.
Inhibition of mitochondrial fission hinders 
CCCP- and Parkin-dependent mitophagy
In DRP1
/MEFs (Ishihara et al., 2009) that display excessively 
fused mitochondria, we observed a noticeable decrease in   
Parkin-induced mitophagy compared with identically treated JCB • VOLUME 191 • NUMBER 7 • 2010   1376
Opa1 is processed by proteases into a fusion-inactive form;   
second, after Parkin translocation to depolarized mitochondria, 
Mfn1 and Mfn2 are degraded in a Parkin-, p97-, and proteasome-
dependent manner to prevent mitochondrial refusion. These two 
pathways may strengthen the isolation of dysfunctional mito-
chondria from healthy mitochondria within a cell by eliminat-
ing fusion of the inner mitochondrial membrane and OMM, 
respectively. Under low-stress conditions, mitochondrial fusion 
may aid the rescue of mitochondrial damage, such as the   
rescue of respiratory chain complex activities or membrane 
important  for  the  promotion  of  mitochondrial  fragmentation 
that might facilitate subsequent mitophagy.
The finding that mitochondrial elongation by DRP1 knock-
out or knockdown inhibits Parkin-mediated mitophagy is con-
sistent  with  the  model  proposed  here.  We  suggest  that  the 
inhibition of mitochondrial fusion may isolate damaged mito-
chondria from healthy mitochondria and thereby promote au-
tophagy of defective organelles. The data shown here indicate that 
during Parkin-driven mitophagy, mitochondria lose fusion activity 
through two pathways. First, immediately after depolarization, 
Figure 7.  Parkin-promoted mitofusin degra-
dation prevents refusion of damaged mitochon-
dria  with  healthy  mitochondria.  (a)  Scheme 
of washout design. HeLa cells or HeLa cells 
stably transfected with YFP-Parkin (green) were 
treated with CCCP for 90 min. (b and c) After 
washing CCCP out and further culture, cells 
were  immunostained  (b)  and  immunoblotted 
(c) with anti-Tom20, VDAC, Mfn1, Opa1, and 
Parkin. CCCP, 10 µM for 90 min. Bar, 10 µm. 
Molecular mass is indicated in kilodaltons next 
to the gel blots. (d) The recovery rate of the 
mitochondrial network as in b was plotted. At 
least 100 cells were counted for the cells with 
connected networks of mitochondria. (e) After 
CCCP  treatment  for  90  min  with  or  without 
washing out CCCP, HeLa cells transiently ex-
pressing Mito-YFP with mCherry empty vector 
(vector) or mCherry-Parkin (Parkin) were sub-
jected to FRAP assays. The curve represents an 
average of 30 individual FRAP curves. (f) The 
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(Exner et al., 2007; Dagda et al., 2009; Lutz et al., 2009;   
Sandebring et al., 2009). As PINK1 functions upstream of Parkin, 
the model proposed here of Parkin-mediated Mfn degradation 
would argue the converse: that activation of the PINK1–Parkin 
pathway would promote fragmentation of mitochondria as sug-
gested by results in fly models. To reconcile the differences de-
scribed in fly and mammalian systems, we suggest that loss of 
PINK1 or Parkin function might exacerbate the accumulation of 
mitochondrial damage due to defective removal of damaged   
mitochondria, and that this excessive damage results in mito-
chondrial fragmentation. Obviously, further studies are required 
to resolve this issue.
potential, by shuffling materials from healthy to damaged mito-
chondria (Chen et al., 2005). However, once mitochondria are 
seriously damaged, they are removed from a cell by autophagy. 
In this pathway, mitochondrial fission accelerates the isolation 
of damaged mitochondria, and recent work has shown that fis-
sion precedes mitophagy (Nowikovsky et al., 2007; Twig et al., 
2008; Kanki et al., 2009). We propose that inhibition of mito-
chondrial fusion during Parkin-driven mitophagy contributes to 
an enhanced rate and selectivity of mitophagy, facilitating mito-
chondrial quality control.
Several recent studies suggest that in mammalian cells, 
reducing PINK1 activity causes mitochondrial fragmentation 
Figure 8.  Mitochondrial fission is required for Parkin-mediated mitophagy. (a) MEFs from DRP1
+/+ or DRP1
/ mice were transiently transfected with 
YFP-Parkin. Cells were treated with CCCP and then immunostained with anti-Tom20. Cells expressing YFP-Parkin are indicated with asterisks. CCCP, 20 µM.   
Bar, 10 µm. (b) Whole cell lysates from DRP1
+/+ or DRP1
/ MEFs with or without transient expression of Parkin were subjected to SDS-PAGE. Molecular 
mass is indicated in kilodaltons next to the gel blots. (c) The average of the Mfn1 or Mfn2 level normalized to the level of Tim23 is presented with the 
standard deviation indicated by the error bars. Each graph was generated from three independent experiments from b. The protein levels in control 
(nontreated, nontransfected) cells were set as 1. (d) Clumping mitochondria in DRP1
+/+ or DRP1
/ MEFs transiently expressing mCherry-Parkin and   
Mito-YFP were subjected to the FRAP assay. The curve represents an average of 30 individual FRAP curves. CCCP, 20 µM for 8 h. (e) The mobile fractions of   
Mito-YFP in d. (f and g) YFP-Parkin translocation (f) and YFP-Parkin–induced mitophagy (g) in DRP1
+/+ or DRP1
/ MEFs treated with CCCP as in panel a were 
quantified (n > 50). CCCP, 20 µM for 24 h. Data represent the mean ± SD with P values of at least three replicates. (h) HeLa cells treated with DRP1 shRNA   
or control HeLa cells were transiently transfected with YFP-Parkin and treated with or without CCCP. Mitochondria were immunostained with anti-Tom20. 
Cells expressing YFP-Parkin are indicated with asterisks. CCCP, 10 µM for 24 h. Bar, 10 µm. (i) YFP-Parkin–induced mitophagy in HeLa cells with or   
without DRP1 RNAi as in h was quantified (n > 50). CCCP, 10 µM for 24 h. Data represent the mean ± SD with P values of at least three replicates.   
(j and k) YFP-Parkin–induced mitophagy in MFN1
+/+2
+/+ MEFs or MFN1
/2
/ MEFs was observed (j) and quantified (k) (n > 50). CCCP, 20 µM for 
24 h. Data represent the mean ± SD with P values of at least three replicates. Cells expressing YFP-Parkin are indicated with asterisks. (l) A model for 
Parkin-mediated Mfn degradation and mitophagy. Depolarized mitochondria (orange) that accumulated PINK1 (gray) are sensed by Parkin (green). After 
Parkin recruitment to the damaged mitochondria, mitochondrial Parkin induces mitofusin (blue) ubiquitination and degradation. Degradation of mitofusin 
is regulated by p97 (purple) and is important to prevent impaired mitochondria from fusing with the vital mitochondrial network. Damaged mitochondria 
isolated by Parkin are engaged with autophagosomes and eliminated by auto-lysosomes.JCB • VOLUME 191 • NUMBER 7 • 2010   1378
supplemented with 10% heat-inactivated fetal calf serum (Gemini Bio-
Products), 100 U/ml penicillin, and 100 µg/ml streptomycin (Invitrogen). 
HCT116 cells were maintained in complete McCoy’s 5A medium supple-
mented with 10% heat-inactivated fetal calf serum (Gemini Bio-Products), 
100 U/ml penicillin, and 100 µg/ml streptomycin (Invitrogen) in 5% CO2 
at 37°C. HCT116 MARCH5 knockout cells were generously supplied by 
C. Wang (National Institutes of Health, Bethesda, MD). DRP1 knockout 
MEFs were supplied by K. Mihara (Kyushu University, Fukuoka, Japan) 
and N. Ishihara (Kurume University, Fukuoka, Japan). MFN1/2 knockout 
MEFs were provided by D. Chan (California Institute of Technology,   
Pasadena, CA).
Antibodies
Anti-Mfn1 and Mfn2 antibodies were generated as described previously 
(Karbowski et al., 2007). Commercial antibodies were purchased as fol-
lows: Opa1 (BD), Fis1 (Enzo Life Sciences, Inc.), Drp1 (BD), VDAC (EMD), 
Tim23 (BD), Hsp60 (Stressgen), Bip (BD), Tom 20 (BD), Tom40 (Santa Cruz 
Biotechnology, Inc.), cytochrome c (BD), Ub (P4D1 [Santa Cruz Biotechnol-
ogy, Inc.] or Fk1 [Enzo Life Sciences, Inc.]), PINK1 (BD), Parkin (PRK8; 
Santa Cruz Biotechnology, Inc.), and p97 (Thermo Fisher Scientific). Sec-
ondary antibodies for the immunostaining were rabbit or mouse Alexa 
Fluor 488, Alexa Fluor 594, or Alexa Fluor 647 (Invitrogen). Secondary 
antibodies for immunoblotting were HRP-conjugated anti–rabbit or anti–
mouse IgG F (a, b)2 antibodies (GE Healthcare). Western blotting signals 
were detected by ECL-plus regents (GE Healthcare).
Chemicals
CCCP (Sigma-Aldrich), carbonylcyanide p-trifluoromethoxyphenylhydrazone 
(FCCP;  Sigma-Aldrich),  paraquat  (Sigma-Aldrich),  rotenone  (Sigma- 
Aldrich), CHX (Sigma-Aldrich), Tunicamycin (Sigma-Aldrich), and MG132 
(EMD) were prepared from DMSO or water stocks.
DNA and transfection
MBP-Parkin  wild  type  and  T415N  were  a  gift  from  K.  Tanaka  and   
N. Matsuda (Tokyo Metropolitan Medical Institute, Tokyo, Japan). Myc-
p97 and Myc-p97
QQ (E305Q/E578Q) were a gift from S. Fang (Univer-
sity of Maryland, Baltimore, MD). The plasmids carrying shRNA sequences 
for  DRP1,  Mito-YFP,  mCherry-Parkin,  YFP-Parkin  (wild  type,  R275W, 
C441R), and Mfn2-YFP have been described previously (Karbowski et al., 
2007; Narendra et al., 2008, 2010). Transfections were performed with 
Effectene (QIAGEN) or Fugene 6 HD (Roche). The experiments were per-
formed 16 h after transfections. To select DRP1 knockdown cells, cells were 
treated with 300 µg/ml of Hygromycin for 3 d, then cultured with 50 µg/ml 
for 3 d. Selected cells were split again 1 d before assays.
Cell fractionation and IP
Cells  were  collected  in  a  buffer  (220  mM  mannitol,  70  mM  sucrose,   
20 mM Hepes-KOH, pH 7.5, 1 mM EDTA, 0.5 mM PMSF, 2 mg/ml BSA, 
and protease inhibitor cocktail [Roche]), then homogenized by 20 pas-
sages through a 25-G syringe (Tyco) on ice. Homogenates were separated 
to the postnuclear supernatant (PNS) by 1,000 g for 10 min at 4°C. The 
PNS  was  further  separated  into  the  mitochondria,  and  the  postmito-
chondrial  fractions  were  separated  by  the  step-wise  centrifugations   
(3,000 g for 10 min and 16,000 g for 15 min). Both pellets were com-
bined as the mitochondrial fraction. Pellets from each fraction were washed 
several times with homogenization buffer (250 mM sucrose, 20 mM Hepes-
KOH, pH 7.5, and protease inhibitor cocktail [Roche]), to remove the   
excess of YFP-Parkin proteins. An IP assay with denaturing condition was 
performed as follows: cell lysates were denatured in TSD buffer (50 mM 
Tris-HCL, pH 7.5, 1.0% SDS, and 5 mM DTT), then diluted with TNN buffer 
(20 mM Tris-HCl, pH7.5, 200 mM NaCl, 0.5% NP-40, and protease   
inhibitor cocktail). The mixtures were subjected to the IP assay with anti-
Mfn1 antibody and protein A/G–Sepharose (Santa Cruz Biotechnology, 
Inc.). Nondenatured IP was performed with IP buffer (50 mM Tris-HCl,   
pH 7.5, 200 mM NaCl, 2.0% CHAPS, and protease inhibitor cocktail) 
and protein A/G–Sepharose.
Immunofluorescence and microscopy
Cells were fixed with 4% PFA/PBS solution for 15 min at 25°C, then per-
meabilized by 0.5% Triton X-100/PBS solution for 5 min at 25°C. After 
blocking of samples with 1% BSA/PBS solution for 30 min with gentle 
shaking, the primary and secondary antibody solutions in 1% BSA/PBS 
were treated sequentially. Samples were imaged using an inverted micro-
scope (LSM510 Meta; Carl Zeiss, Inc.) with a 63×/1.4 NA oil DIC Plan-
Apochromat objective lens at 25°C.
Membrane-spanning proteins resident in the ER can be 
degraded by the proteasome after ubiquitination and retrotrans-
location from the ER membrane. The results shown here indi-
cate that Mitofusin degradation by the proteasome is an example 
of a related process occurring at the OMM. We have shown pre-
viously that upon cell cycle arrest, Fzo1 (the yeast Mfn ortho-
logue) is ubiquitinated on the OMM (Neutzner et al., 2007) and 
degraded by the proteasome (Neutzner and Youle, 2005; Escobar-
Henriques et al., 2006; Cohen et al., 2008; Amiott et al., 2009). 
In analogy to ER-associated degradation (ERAD), we have pro-
posed the term OMMAD for this OMM-associated degradation 
pathway (Neutzner et al., 2007). In yeast, proteins that may par-
ticipate in Cullin-mediated ubiquitination—the F-Box protein 
MDM30 and the Skp1 proteins—have been found to participate 
in the steady-state proteasomal degradation of Fzo1 during   
vegetative growth (Dürr et al., 2006; Escobar-Henriques et al., 
2006; Cohen et al., 2008), but not during Fzo1 proteasomal deg-
radation upon cell cycle arrest because of  factor (Neutzner 
and Youle, 2005). Here we find that the E3 Ub ligase Parkin 
promotes OMMAD of Mfn1 and Mfn2 in mammalian cells in 
response to mitochondrial uncoupling. Parkin is a RING be-
tween RING-type E3 ligase, which has been proposed to partic-
ipate  in  Cullin  complex–mediated  substrate  ubiquitination 
(Staropoli et al., 2003). This suggests that Cullin and mamma-
lian F-box proteins may also be involved in Parkin-mediated 
mitofusin degradation. Corroborating the idea of an ERAD-like 
process occurring at the mitochondria, we identified a require-
ment for p97 activity for proteasomal elimination of the OMM-
spanning Mfn1 and Mfn2. In addition, as indicated by the effect 
of p97
QQ on Mfn1 ubiquitination in the absence of Parkin ex-
pression, degradation of mitofusins in mammalian cells might 
be mediated by other E3 Ub ligases during steady-state protea-
some-mediated turnover. Furthermore, mitochondrial substrates 
for Parkin-mediated degradation other than Mfn1 and Mfn2 
likely remain to be identified.
We also show that inhibition of p97 activity by the over-
expression  of  dominant-negative  p97  mutant  prevents  the 
PINK1–Parkin-mediated mitochondrial elimination. Although 
this role of p97 in mitophagy correlates with its role in Mfn 
elimination, which suggests that Mfn elimination is required for 
Parkin-mediated mitophagy, p97 may mediate OMMAD of 
other mitochondrial substrates or play a role in the maturation 
of autophagosomes as proposed by Tresse et al. (2010) down-
stream of Mfn elimination. Current studies in our laboratories 
address these interesting possibilities.
Materials and methods
Cell culture
MEFs, HeLa cells, or HeLa cells stably expressing YFP-Parkin (FlpIn system; 
Invitrogen) called HeLa: YFP-Parkin were cultured in complete Dulbecco’s 
minimum essential medium supplemented with 10% heat-inactivated fetal 
calf serum (Gemini Bio-Products), 100 U/ml penicillin, and 100 µg/ml 
streptomycin (Invitrogen) in 5% CO2 at 37°C. Stable cell lines were main-
tained with 250 µg/ml of Zeocin (Invitrogen) or 200 µg/ml of Hygro-
mycin (Sigma-Aldrich). M17 neuroblastoma carrying small hairpin RNA 
(shRNA) for control or PINK1 (Narendra et al., 2010) were maintained 
with  Opti-MEM,  10%  heat-inactivated  fetal  calf  serum  (Gemini  Bio- 
Products), and 10 µg/ml Blastidin (Invitrogen). SH-SY5Y neuroblastoma 
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